ToddAFehnigerMDPhD

Oncology • Saint Louis, MO

Hematologic Oncology

Associate Professor, Internal Medicine, Washington University School of Medicine

Join to view full profile

Dr. Fehniger is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Fehniger's full profile

Already have an account?

Office
4921 Parkview Pl
# Dv
Saint Louis, MO 63110
Phone+1 314-454-8304

Fax+1 314-454-5902

Summary

Dr. Todd Fehniger is an oncologist in Saint Louis, MO and is affiliated with multiple hospitals in the area, including Barnes-Jewish Hospital and Siteman Cancer Center. He received his medical degree from The Ohio State University College of Medicine and has been in practice 15 years. He specializes and is board certified in medical oncology and is experienced in blood cancers (leukemia, lymphoma, and related diseases), hematopoietic cell transplantation (bone marrow transplantation, cellular therapy (CAR T cells).

Education & Training

Washington University/B-JH/SLCH ConsortiumFellowship, Hematology and Medical Oncology, 2004 - 2008
Washington University/B-JH/SLCH ConsortiumResidency, Internal Medicine, 2002 - 2004
Ohio State University College of MedicineClass of 2002

Certifications & Licensure

MO State Medical License 2004 - 2025
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification Allscripts Enterprise EHR, Allscripts, 2012

Clinical Trials

Lenalidomide in Relapsed or Refractory Classical Hodgkin Lymphoma Start of enrollment: 2007 Sep 06
Completed
Phase 2
Lenalidomide Maintenance Therapy Post Autologous Transplant for Hodgkins Lymphoma Start of enrollment: 2011 Apr 28
Completed
Phase 1
CNDO-109-AANK for AML in First Complete Remission (CR1) Start of enrollment: 2012 Dec 01
Unknown status
Phase 1, Phase 2
Phase I/II Study of Abraxane in Recurrent and Refractory Lymphoma Start of enrollment: 2012 Jul 01
Terminated
Phase 1
Cytokine-induced Memory-like NK Cells in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) Start of enrollment: 2014 Aug 11
Terminated
Phase 1, Phase 2
Study of Melphalan HCl for Injection (Propylene Glycol-free), Carmustine, Etoposide, Cytarabine (BEAM Regimen) and Autologous Stem Cell Transplantation for Lymphoma Start of enrollment: 2014 Mar 19
Completed
Phase 2
Allogeneic or Haploidentical Stem Cell Transplant Followed By High-Dose Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Start of enrollment: 2014 Feb 28
Terminated
Phase 1
Brentuximab Vedotin and Lenalidomide for Relapsed or Refractory Diffuse Large B-cell Lymphoma Start of enrollment: 2014 Sep 18
Completed
Phase 1
Non-inferiority Study of XM02 Filgrastim (Granix) and Filgrastim (Neupogen) in Combination With Plerixafor for Autologous Stem Cell Mobilization in Patients With Multiple Myeloma or Non-Hodgkin Lymphoma Start of enrollment: 2014 Aug 20
Completed
Phase 2
QUILT-3.005: A Study of ALT-803 in Patients With Relapsed or Refractory Multiple Myeloma Start of enrollment: 2014 Oct 01
Unknown status
Phase 1
A Study of Granix to Disrupt the Bone Marrow Microenvironment in Patients With Multiple Myeloma Undergoing Autologous Transplantation Start of enrollment: 2015 Jan 20
Terminated
Phase 2
Phase I Study of Romidepsin, Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed/Refractory Aggressive Lymphomas Start of enrollment: 2015 Feb 04
Completed
Phase 1
Phase I Study of Bortezomib With G-CSF for Stem Cell Mobilization in Patients With Multiple Myeloma Start of enrollment: 2015 Feb 20
Completed
Phase 1
Personalized Tumor Vaccine Strategy and PD-1 Blockade in Patients With Follicular Lymphoma Start of enrollment: 2018 Oct 16
Terminated
Phase 1
FT596 With Rituximab as Relapse Prevention After Autologous HSCT for NHL Start of enrollment: 2020 Sep 22
Active, not recruiting
Phase 1
Join now to see all

Publications & Presentations

PubMed

9 citations
T-BET and EOMES sustain mature human NK cell identity and antitumor function.
Pamela Wong, Jennifer A Foltz, Lily Chang, Carly C Neal, Tony Yao
The Journal of Clinical Investigation. 2023-07-03
40 citations
Stage-Specific Requirement for Eomes in Mature NK Cell Homeostasis and Cytotoxicity
Julia A. Wagner, Pamela Wong, Timothy Schappe, Melissa M. Berrien-Elliott, Celia C. Cubitt
Cell Reports. 2020-06-02
2144 citations
The biology of human natural killer-cell subsets.
Megan A. Cooper, Todd A. Fehniger, Michael A. Caligiuri
Trends in Immunology. 2001-11-01

Journal Articles

A Deep Learning Approach to Automate Refinement of Somatic Variant Calling from Cancer Sequencing Data
Ravindra Uppaluri, Gavin P Dunn, Ramaswamy Govindan, S Joshua Swamidass, Todd A Fehniger, Nature
Single Institution Experience with G-CSF Mobilized T-cell Replete Haploidentical Hematopoietic Cell Transplantation
M A Schroeder, R Romee, J F DiPersio, T A Fehniger, F Gao, G L Uy, C N Abboud, P Westervelt, R Vij, Nature

Abstracts/Posters

System-Level Disease-Driven Immune Signatures in Patients with Diffuse Large B-Cell Lymphoma Associated with Poor Survival
Todd A Fehniger, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Chimeric Antigen Receptor Modified Memory-like (CAR-ML) NK Cells Exhibit Potent Responses to NK-Resistant Tumors
Todd A Fehniger, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Adoptively Transferred Donor-Derived Cytokine Induced Memory-like NK Cells Persist and Induce Remission in Pediatric Patient with Relapsed Acute Myeloid Leukemia after...
Todd A Fehniger, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Primary Human NK Cell Gene-Editing Reveals a Critical Role for NKG2A in Cytokine-Induced Memory-like NK Cell Responses
Todd A Fehniger, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Cytokine-Induced Memory-like (ML) NK Cells Persist for > 2 Months Following Adoptive Transfer into Leukemia Patients with a MHC-Compatible Hematopoietic Cell Transplan...
Todd A Fehniger, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Romidepsin in Combination with Gemcitabine, Oxaliplatin, and Dexamethasone Shows Durable Responses in Aggressive Lymphomas
Todd A Fehniger, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Potently Cytotoxic Natural Killer Cell Potential Initially Emerges from Erythro-Myeloid Progenitors during Mammalian Development
Todd A Fehniger, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Join now to see all

Lectures

The Making of Memory
60th American Society of Hematology Annual Meeting - 12/1/2018
Ontogeny As a Critical Determinant of Natural Killer Cell Potential and Function
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

For Children, Young Adults with Recurrent AML, Immunotherapy Shows PromiseDecember 10th, 2021
Wugen Raises $172 Million to Advance Clinical Stage Memory NK Cell Platform, Progress Best-in-Class AML Program, and Initiate Multiple Solid Tumor TrialsJuly 15th, 2021
Affimed Announces Publication of Preclinical Data in Clinical Cancer Research Supporting Therapeutic Potential of AFM13 in Combination with Natural Killer CellsMay 13th, 2021
Join now to see all